{"id":1342,"date":"2026-08-07T12:03:31","date_gmt":"2026-08-07T09:03:31","guid":{"rendered":"https:\/\/life-peptide.com\/?page_id=1342"},"modified":"2026-08-07T12:03:33","modified_gmt":"2026-08-07T09:03:33","slug":"retatrutide-vs-tirzepatide","status":"publish","type":"page","link":"https:\/\/life-peptide.com\/cs\/retatrutide-vs-tirzepatide\/","title":{"rendered":"Retatrutid vs. Tirzepatid: Jak\u00fd je mezi nimi rozd\u00edl?"},"content":{"rendered":"<h1 class=\"wp-block-heading\">Retatrutid vs. Tirzepatid: Jak\u00fd je mezi nimi rozd\u00edl?<\/h1>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\">Retatrutid <\/a>a <a href=\"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid <\/a>jsou dva \u00fazce p\u0159\u00edbuzn\u00e9 metabolick\u00e9 peptidy, kter\u00e9 se v\u0161ak v jednom z\u00e1sadn\u00edm ohledu li\u0161\u00ed: <strong>Tirzepatid aktivuje dva receptory metabolick\u00fdch hormon\u016f, zat\u00edmco Retatrutid aktivuje t\u0159i.<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatid je du\u00e1ln\u00ed agonist\u00e9 receptor\u016f GIP\/GLP-1 s rozs\u00e1hlou klinickou evidenc\u00ed a regulatorn\u00edm schv\u00e1len\u00edm pro metabolick\u00e9 indikace. Retatrutid p\u0159id\u00e1v\u00e1 aktivitu glukagonov\u00e9ho receptoru (GCGR) k agonismu receptor\u016f GIP a GLP-1 a je zkoum\u00e1n jako trojit\u00fd agonist\u00e9 nov\u00e9 generace.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Toto srovn\u00e1n\u00ed zkoum\u00e1 rozd\u00edly mezi retatrutidem a tirzepatidem v aktivit\u011b receptor\u016f, mechanismu, publikovan\u00fdch zji\u0161t\u011bn\u00edch t\u00fdkaj\u00edc\u00edch se \u00fabytku hmotnosti, metabolick\u00fdch \u00fa\u010dinc\u00edch, klinick\u00e9m v\u00fdvoji a sou\u010dasn\u00e9m stavu v\u00fdzkumu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Retatrutid vs. Tirzepatid v p\u0159ehledu<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Charakteristika<\/th><th>Retatrutid<\/th><th>Tirzepatid<\/th><\/tr><\/thead><tbody><tr><td>Typ peptidu<\/td><td>Trojit\u00fd receptorov\u00fd agonista<\/td><td>Du\u00e1ln\u00ed receptorov\u00fd agonista<\/td><\/tr><tr><td>GLP-1 receptor<\/td><td>\u2713<\/td><td>\u2713<\/td><\/tr><tr><td>GIP receptor<\/td><td>\u2713<\/td><td>\u2713<\/td><\/tr><tr><td>Glukagonov\u00fd receptor<\/td><td>\u2713<\/td><td>\u2014<\/td><\/tr><tr><td>Hlavn\u00ed oblast v\u00fdzkumu<\/td><td>Obezita a metabolick\u00e9 onemocn\u011bn\u00ed<\/td><td>Obezita, regulace hmotnosti a cukrovka 2. typu<\/td><\/tr><tr><td>Publikovan\u00e9 studie o obezit\u011b<\/td><td>Data z f\u00e1ze 2 a prob\u00edhaj\u00edc\u00ed f\u00e1ze 3<\/td><td>Rozs\u00e1hl\u00fd program 3. f\u00e1ze<\/td><\/tr><tr><td>Regulatorn\u00ed status<\/td><td>Zkouman\u00fd<\/td><td>Schv\u00e1len\u00fd l\u00e9k<\/td><\/tr><tr><td>P\u0159ibli\u017en\u00fd polo\u010das rozpadu<\/td><td>~6 dn\u00ed<\/td><td>~5 dn\u00ed<\/td><\/tr><tr><td>Frekvence d\u00e1vkov\u00e1n\u00ed zkouman\u00e1 v klinick\u00fdch studi\u00edch<\/td><td>Jednou t\u00fddn\u011b<\/td><td>Jednou t\u00fddn\u011b<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Nejd\u016fle\u017eit\u011bj\u0161\u00ed rozd\u00edl tedy nen\u00ed v tom, \u017ee by tyto dv\u011b slou\u010deniny pat\u0159ily do zcela odli\u0161n\u00fdch t\u0159\u00edd. Sp\u00ed\u0161e, <strong>Retatrutid roz\u0161i\u0159uje koncept du\u00e1ln\u00edho agonisty, kter\u00fd zavedl tirzepatid, zaveden\u00edm aktivity glukagonov\u00e9ho receptoru.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Co je <a href=\"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid<\/a>?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatid je \u00fa\u010dinn\u00e1 farmaceutick\u00e1 l\u00e1tka pou\u017e\u00edvan\u00e1 v komer\u010dn\u00edch l\u00e9c\u00edch <strong>Mounjaro a Zepbound<\/strong>. Je to syntetick\u00fd peptid navr\u017een\u00fd tak, aby aktivoval oba <strong>receptor pro gluk\u00f3zo-dependentn\u00ed insulinotropn\u00ed polypeptid (GIP) a receptor pro glukagonu podobn\u00fd peptid-1 (GLP-1)<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Signaling receptor\u016f GLP-1 je spojeno s gluk\u00f3zo-dependentn\u00ed sekrec\u00ed inzulinu, sn\u00ed\u017eenou sekrec\u00ed glukagonu za hyperglykemick\u00fdch podm\u00ednek, zpomalen\u00fdm vypr\u00e1zd\u0148ov\u00e1n\u00edm \u017ealudku a regulac\u00ed chuti k j\u00eddlu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">GIP poskytuje dodate\u010dnou inkretinovou dr\u00e1hu, kter\u00e1 se pod\u00edl\u00ed na sekreci inzul\u00ednu, zpracov\u00e1n\u00ed \u017eivin a metabolick\u00e9 regulaci.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Spojen\u00ed t\u011bchto dvou drah v jedn\u00e9 molekule p\u0159edstavovalo v\u00fdznamn\u00fd posun nad r\u00e1mec agonist\u016f receptoru GLP-1, jako je semaglutid.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatid byl n\u00e1sledn\u011b zkoum\u00e1n v r\u00e1mci rozs\u00e1hl\u00e9ho klinick\u00e9ho programu zahrnuj\u00edc\u00edho diabetes 2. typu, obezitu a souvisej\u00edc\u00ed metabolick\u00e9 stavy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Co je <a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\">Retatrutid<\/a>?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Retatrutide je syntetick\u00fd peptidov\u00fd agonista c\u00edl\u00edc\u00ed na <strong>t\u0159i receptory sou\u010dasn\u011b: GIP, GLP-1 a glukagon (GCG\/GCGR).<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Prvn\u00ed dva c\u00edle se p\u0159ekr\u00fdvaj\u00ed s tirzepatidem. Hlavn\u00edm rozd\u00edlem je p\u0159id\u00e1n\u00ed agonismu glukagonov\u00e9ho receptoru.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Glukagon je b\u011b\u017en\u011b spojov\u00e1n s regulac\u00ed gluk\u00f3zy v j\u00e1trech, av\u0161ak signalizace glukagonov\u00e9ho receptoru ovliv\u0148uje tak\u00e9 metabolismus lipid\u016f, vyu\u017eit\u00ed substr\u00e1t\u016f a v\u00fddej energie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u016fvodem pro pou\u017eit\u00ed retatrutidu je proto kombinace \u00fa\u010dink\u016f na chu\u0165 k j\u00eddlu a metabolismus spojen\u00fdch se signalingem inkretin\u016f s dal\u0161\u00ed dr\u00e1hou, kter\u00e1 potenci\u00e1ln\u011b ovliv\u0148uje v\u00fddej energie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To vedlo k tomu, \u017ee je retatrutide ozna\u010dov\u00e1n jako <strong>trojit\u00fd agonista<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Kl\u00ed\u010dov\u00fd rozd\u00edl: du\u00e1ln\u00ed vs. triplexn\u00ed agonismus<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Postup mezi n\u011bkolika hlavn\u00edmi t\u0159\u00eddami metabolick\u00fdch peptid\u016f lze zjednodu\u0161it takto:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/life-peptide.com\/cs\/product\/semaglutide-10-mg\/\" data-type=\"product\" data-id=\"303\">Semaglutid <\/a>\u2192 GLP-1<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid<\/a> \u2192 GIP + GLP-1<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\">Retatrutid <\/a>\u2192 GIP + GLP-1 + glukagon<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pouh\u00e9 po\u010d\u00edt\u00e1n\u00ed receptor\u016f v\u0161ak nestanovuje, \u017ee jedna slou\u010denina je inherentn\u011b \u201clep\u0161\u00ed\u201d ne\u017e jin\u00e1. Biologick\u00fd \u00fa\u010dinek z\u00e1vis\u00ed na faktorech, mezi kter\u00e9 pat\u0159\u00ed potence receptor\u016f, rovnov\u00e1ha receptor\u016f, farmakokinetika, d\u00e1vka a charakteristiky zkouman\u00e9 populace.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dodate\u010dn\u00e1 slo\u017eka glukagonu je nicm\u00e9n\u011b ur\u010duj\u00edc\u00edm farmakologick\u00fdm rozd\u00edlem mezi retatrutidem a tirzepatidem.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Pro\u010d p\u0159idat aktivitu glukagonov\u00e9ho receptoru?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Signaling GLP-1 a GIP prim\u00e1rn\u011b ovliv\u0148uj\u00ed chu\u0165 k j\u00eddlu, regulaci gluk\u00f3zy a metabolismus \u017eivin. Aktivace glukagonov\u00e9ho receptoru zav\u00e1d\u00ed dal\u0161\u00ed metabolickou dr\u00e1hu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Experiment\u00e1ln\u00ed d\u016fkazy nazna\u010duj\u00ed, \u017ee signalizace glukagonu m\u016f\u017ee zv\u00fd\u0161it v\u00fddej energie a ovlivnit oxidaci lipid\u016f a vyu\u017eit\u00ed substr\u00e1t\u016f. V\u011bdci proto zkoumali, zda by pe\u010dliv\u011b vyv\u00e1\u017een\u00e1 aktivita glukagonu mohla doplnit \u00fa\u010dinky vyvolan\u00e9 agonismem GLP-1 a GIP.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Retatrutide p\u0159edstavuje jeden z nejpokro\u010dilej\u0161\u00edch klinick\u00fdch test\u016f t\u00e9to strategie se t\u0159emi receptory.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Retatrutide vs Tirzepatide: zji\u0161t\u011bn\u00ed t\u00fdkaj\u00edc\u00ed se \u00fabytku hmotnosti<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ob\u011b slou\u010deniny vedly v pr\u016fb\u011bhu klinick\u00fdch hodnocen\u00ed k podstatn\u00e9mu sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti. P\u0159\u00edm\u00e9 srovn\u00e1n\u00ed v\u0161ak vy\u017eaduje opatrnost, proto\u017ee hlavn\u00ed studie zam\u011b\u0159en\u00e9 na ob\u011bdvnictv\u00ed pro p\u0159\u00edpravky Retatrutide a Tirzepatide byly <strong>samostatn\u00e9 studie zahrnuj\u00edc\u00ed r\u016fzn\u00e9 \u00fa\u010dastn\u00edky, protokoly, d\u00e9lky l\u00e9\u010dby a d\u00e1vky<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ne\u0161lo o studie typu head-to-head.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Tirzepatid<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ve studii f\u00e1ze 3 SURMOUNT-1 byli dosp\u011bl\u00ed s obezitou nebo nadv\u00e1hou bez cukrovky sledov\u00e1ni po dobu 72 t\u00fddn\u016f.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pr\u016fm\u011brn\u00e9 zm\u011bny t\u011blesn\u00e9 hmotnosti byly:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>D\u00e1vkov\u00e1n\u00ed tirzepatidu<\/th><th>Pr\u016fm\u011brn\u00e1 zm\u011bna hmotnosti v 72. t\u00fddnu<\/th><\/tr><\/thead><tbody><tr><td>5 mg<\/td><td>\u221215,01 TP3T<\/td><\/tr><tr><td>10 mg<\/td><td>\u221219,51 TP3T<\/td><\/tr><tr><td>15 mg<\/td><td>\u221220,91 TP3T<\/td><\/tr><tr><td>Placebo<\/td><td>\u22123,11 TP3T<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Tyto v\u00fdsledky za\u0159adily tirzepatid mezi nej\u00fa\u010dinn\u011bj\u0161\u00ed metabolick\u00e9 l\u00e1tky zkouman\u00e9 ve velk\u00fdch klinick\u00fdch studi\u00edch obezity f\u00e1ze 3.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Retatrutid<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">V publikovan\u00e9 klinick\u00e9 studii f\u00e1ze 2 s retatrulidem zam\u011b\u0159en\u00e9 na obezitu byli dosp\u011bl\u00ed s obezitou nebo nadv\u00e1hou sledov\u00e1ni po dobu 48 t\u00fddn\u016f.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pr\u016fm\u011brn\u00e9 zm\u011bny t\u011blesn\u00e9 hmotnosti zahrnovaly:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>D\u00e1vkov\u00e1n\u00ed retatrutidu<\/th><th>Pr\u016fm\u011brn\u00e1 zm\u011bna hmotnosti ve 48 t\u00fddnech<\/th><\/tr><\/thead><tbody><tr><td>1 mg<\/td><td>\u22128,71 TP3T<\/td><\/tr><tr><td>4 mg kombinovan\u00e9 skupiny<\/td><td>\u221217,11 TP3T<\/td><\/tr><tr><td>kombinovan\u00e9 skupiny 8 mg<\/td><td>\u221222,81 TP3T<\/td><\/tr><tr><td>12 mg<\/td><td>\u221224,21 TP3T<\/td><\/tr><tr><td>Placebo<\/td><td>\u22122,11 TP3T<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">P\u0159i nejvy\u0161\u0161\u00ed zkouman\u00e9 d\u00e1vce dos\u00e1hlo pr\u016fm\u011brn\u00e9 sn\u00ed\u017een\u00ed <strong>24,21 TP3T ve 48. t\u00fddnu<\/strong>. D\u016fle\u017eit\u00e9 je, \u017ee k\u0159ivka \u00fabytku hmotnosti v publikovan\u00e9 studii 2. f\u00e1ze nebyla ve 48. t\u00fddnu z\u0159eteln\u011b ust\u00e1len\u00e1.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tyto poznatky vyvolaly zna\u010dn\u00fd v\u00fdzkumn\u00fd z\u00e1jem o to, zda trojn\u00e1sobn\u00fd agonismus GIP\/GLP-1\/glukagonu by mohl roz\u0161\u00ed\u0159it metabolick\u00e9 \u00fa\u010dinky pozorovan\u00e9 u d\u0159\u00edv\u011bj\u0161\u00edch slou\u010denin zalo\u017een\u00fdch na inkretinu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Lze procenta retatrutidu a tirzepatidu porovn\u00e1vat p\u0159\u00edmo?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Nespolehliv\u011b.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Je l\u00e1kav\u00e9 porovnat hodnotu 24,21 TP3T u retatrutidu s hodnotou 20,91 TP3T u tirzepatidu a doj\u00edt k z\u00e1v\u011bru, \u017ee retatrutid vedl k \u00fabytku hmotnosti o p\u0159ibli\u017en\u011b t\u0159i procentn\u00ed body v\u00edce. To by v\u0161ak byla p\u0159\u00edli\u0161 zjednodu\u0161uj\u00edc\u00ed interpretace.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Obr\u00e1zek retatrutidu poch\u00e1z\u00ed z <strong>48t\u00fddenn\u00ed studie f\u00e1ze 2<\/strong>, zat\u00edmco \u00fadaj o tirzepatidu poch\u00e1zel z <strong>72t\u00fddenn\u00ed studie f\u00e1ze 3<\/strong>. Studie se li\u0161ily v uspo\u0159\u00e1d\u00e1n\u00ed, charakteristik\u00e1ch \u00fa\u010dastn\u00edk\u016f, titra\u010dn\u00edch protokolech a dal\u0161\u00edch prom\u011bnn\u00fdch. Skute\u010dn\u00e9 porovn\u00e1n\u00ed \u00fa\u010dinnosti by v ide\u00e1ln\u00edm p\u0159\u00edpad\u011b vy\u017eadovalo randomizovanou srovn\u00e1vac\u00ed studii.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dostupn\u00e9 d\u016fkazy tedy podporuj\u00ed tvrzen\u00ed, \u017ee <strong>ob\u011b slou\u010deniny prok\u00e1zaly v klinick\u00e9m v\u00fdzkumu neobvykle velk\u00fd \u00fabytek hmotnosti<\/strong>, zat\u00edmco v\u00fdsledky f\u00e1ze 2 retatrutidu poskytly p\u00e1dn\u00fd d\u016fvod pro dal\u0161\u00ed zkoum\u00e1n\u00ed trojit\u00e9ho agonismu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Metabolick\u00e9 \u00fa\u010dinky p\u0159esahuj\u00edc\u00ed t\u011blesnou hmotnost<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Z\u00e1jem v\u00fdzkumu o oba peptidy p\u0159esahuje r\u00e1mec sni\u017eov\u00e1n\u00ed hmotnosti.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatid byl podrobn\u011b studov\u00e1n ohledn\u011b vlivu na:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>glykemick\u00e1 kontrola<\/li>\n\n\n\n<li>inzulinov\u00e1 citlivost<\/li>\n\n\n\n<li>la\u010dn\u00fd cukr<\/li>\n\n\n\n<li>HbA1c<\/li>\n\n\n\n<li>obvod pasu<\/li>\n\n\n\n<li>lipidov\u00e9 parametry<\/li>\n\n\n\n<li>krevn\u00ed tlak<\/li>\n\n\n\n<li>n\u011bkolik stav\u016f spojen\u00fdch s obezitou<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">V\u00fdzkum retatrutidu podobn\u011b zaznamenal zm\u011bny v cel\u00e9 \u0159ad\u011b kardiometabolick\u00fdch ukazatel\u016f. Jeho slo\u017eka glukagonov\u00e9ho receptoru je mimo\u0159\u00e1dn\u011b zaj\u00edmav\u00e1, proto\u017ee m\u016f\u017ee ovliv\u0148ovat energetick\u00fd v\u00fddej a metabolismus lipid\u016f prost\u0159ednictv\u00edm mechanism\u016f, kter\u00e9 se li\u0161\u00ed od \u010dist\u00e9 inkretinov\u00e9 signalizace.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To p\u0159edstavuje jednu z nejd\u016fle\u017eit\u011bj\u0161\u00edch mechanistick\u00fdch ot\u00e1zek t\u00fdkaj\u00edc\u00edch se trojit\u00fdch agonist\u016f.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Retatrutid vs. tirzepatid \u2013 polo\u010das vylu\u010dov\u00e1n\u00ed<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Oba peptidy byly navr\u017eeny pro prodlou\u017eenou biologickou aktivitu kompatibiln\u00ed s pod\u00e1v\u00e1n\u00edm jednou t\u00fddn\u011b v klinick\u00fdch studi\u00edch.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elimina\u010dn\u00ed polo\u010das tirzepatidu je p\u0159ibli\u017en\u011b <strong>p\u011bt dn\u00ed<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">U retatrutidu se uv\u00e1d\u00ed polo\u010das elimina\u010dn\u00edho rozpadu p\u0159ibli\u017en\u011b <strong>\u0161est dn\u00ed<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Jejich farmakokinetick\u00e9 profily jsou proto v z\u00e1sad\u011b podobn\u00e9, pokud jde o frekvenci d\u00e1vkov\u00e1n\u00ed zkoumanou v klinick\u00fdch studi\u00edch, a to navzdory jejich odli\u0161n\u00fdm receptorov\u00fdm profil\u016fm.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Bezpe\u010dnost a sn\u00e1\u0161enlivost v klinick\u00e9m v\u00fdzkumu<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ob\u011b slou\u010deniny vyvolaly gastrointestin\u00e1ln\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky typick\u00e9 pro metabolick\u00e9 terapie zalo\u017een\u00e9 na inkretinu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u010casto hl\u00e1\u0161en\u00e9 ud\u00e1losti zahrnuj\u00ed:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>nevolnost<\/li>\n\n\n\n<li>pr\u016fjem<\/li>\n\n\n\n<li>zvracen\u00ed<\/li>\n\n\n\n<li>z\u00e1cpa<\/li>\n\n\n\n<li>sn\u00ed\u017een\u00e1 chu\u0165 k j\u00eddlu<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Tyto \u00fa\u010dinky byly obecn\u011b nejv\u00fdrazn\u011bj\u0161\u00ed b\u011bhem zvy\u0161ov\u00e1n\u00ed d\u00e1vky.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">V klinick\u00e9 studii f\u00e1ze 2 s retatrutidem byly gastrointestin\u00e1ln\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky z\u00e1visl\u00e9 na d\u00e1vce a p\u0159ev\u00e1\u017en\u011b m\u00edrn\u00e9 a\u017e st\u0159edn\u011b z\u00e1va\u017en\u00e9. Bylo rovn\u011b\u017e pozorov\u00e1no zv\u00fd\u0161en\u00ed srde\u010dn\u00ed frekvence z\u00e1visl\u00e9 na d\u00e1vce, kter\u00e9 dos\u00e1hlo vrcholu b\u011bhem studie a n\u00e1sledn\u011b kleslo. Tirzepatid m\u00e1 podstatn\u011b v\u011bt\u0161\u00ed bezpe\u010dnostn\u00ed soubor dat d\u00edky sv\u00e9mu rozs\u00e1hl\u00e9mu programu v\u00fdvoje ve f\u00e1zi 3 a n\u00e1sledn\u00e9mu klinick\u00e9mu pou\u017eit\u00ed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tento rozd\u00edl v \u00farovni v\u011bdeck\u00fdch d\u016fkaz\u016f je d\u016fle\u017eit\u00fd p\u0159i porovn\u00e1v\u00e1n\u00ed obou l\u00e1tek.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Vyzr\u00e1lost v\u00fdzkumu: d\u016fle\u017eit\u00fd rozd\u00edl<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Receptorov\u00fd profil nen\u00ed jedin\u00fdm z\u00e1sadn\u00edm rozd\u00edlem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tirzepatid je ji\u017e zaveden\u00e1 farmaceutick\u00e1 slou\u010denina s regulovan\u00fdm schv\u00e1len\u00edm a velmi rozsiahlymi klinick\u00fdmi d\u016fkazy.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">V roce 2022 obdr\u017eela registraci k uv\u00e1d\u011bn\u00ed na trh v EU a je schv\u00e1lena pro l\u00e9\u010dbu diabetu 2. typu a kontrolu hmotnosti u vhodn\u00fdch pacient\u016f.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Retatrutide z\u016fst\u00e1v\u00e1 ve f\u00e1zi v\u00fdzkumu.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Jeho zji\u0161t\u011bn\u00ed z 2. f\u00e1ze vedla k rozs\u00e1hl\u00e9mu programu 3. f\u00e1ze TRIUMPH a p\u0159edb\u011b\u017en\u00e9 v\u00fdsledky 3. f\u00e1ze se za\u010daly objevovat v roce 2026. Retatrutid v\u0161ak nez\u00edskal schv\u00e1len\u00ed regula\u010dn\u00edch \u00fa\u0159ad\u016f. V d\u016fsledku toho pro tirzepatid existuje v sou\u010dasnosti mnohem v\u00edce dlouhodob\u00fdch klinick\u00fdch d\u016fkaz\u016f ne\u017e pro retatrutid.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Tak \u010d\u00edm se vlastn\u011b Retatrutid li\u0161\u00ed od Tirzepatidu?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Nejjednodu\u0161\u0161\u00ed odpov\u011b\u010f je <strong>aktivita glukagonov\u00e9ho receptoru<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ob\u011b slou\u010deniny aktivuj\u00ed:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>GIP + GLP-1<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Retatrutide nav\u00edc aktivuje:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>+ glukagon<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tato t\u0159et\u00ed dr\u00e1ha m\u016f\u017ee ovliv\u0148ovat energetick\u00fd v\u00fddej, metabolismus lipid\u016f a vyu\u017eit\u00ed substr\u00e1t\u016f spolu s \u00fa\u010dinky na chu\u0165 k j\u00eddlu a regulaci gluk\u00f3zy, kter\u00e9 jsou spojeny s inkretinovou sinalizac\u00ed. Zda to nakonec p\u0159inese klinicky v\u00fdznamn\u00e9 v\u00fdhody oproti du\u00e1ln\u00edmu agonismu u r\u016fzn\u00fdch populac\u00ed, je p\u0159esn\u011b jednou z ot\u00e1zek, na kter\u00e9 m\u00e1 prob\u00edhaj\u00edc\u00ed v\u00fdzkum retatrutidu odpov\u011bd\u011bt.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Retatrutide vs Tirzepatide: p\u0159ehled v\u00fdzkumu<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatid prok\u00e1zal, \u017ee kombinovan\u00fd agonismus receptor\u016f pro GIP a GLP-1 m\u016f\u017ee vyvolat metabolick\u00e9 \u00fa\u010dinky, kter\u00e9 p\u0159esahuj\u00ed ty, jak\u00e9 byly historicky pozorov\u00e1ny p\u0159i agonismu samotn\u00e9ho receptoru pro GLP-1. Retatrutid tento koncept roz\u0161i\u0159uje o aktivitu receptoru pro glukagon.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Publikovan\u00e9 d\u016fkazy tak p\u0159edstavuj\u00ed zaj\u00edmav\u00fd posun ve v\u00fdzkumu metabolick\u00fdch peptid\u016f:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>jednoduch\u00fd agonismus \u2192 du\u00e1ln\u00ed agonismus \u2192 triplov\u00fd agonismus<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatid m\u00e1 v sou\u010dasnosti mnohem v\u011bt\u0161\u00ed a vyzr\u00e1lej\u0161\u00ed z\u00e1kladnu d\u016fkaz\u016f, v\u010detn\u011b regulatorn\u00edho schv\u00e1len\u00ed a rozs\u00e1hl\u00e9ho v\u00fdzkumu f\u00e1ze 3.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Retatrutide z\u016fst\u00e1v\u00e1 zkoumanou l\u00e1tkou, ale jeho klinick\u00e9 v\u00fdsledky u\u010dinily z trojit\u00e9ho receptorov\u00e9ho agonismu v\u00fdznamnou oblast metabolick\u00e9ho v\u00fdzkumu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kl\u00ed\u010dov\u00e1 v\u011bdeck\u00e1 ot\u00e1zka tedy nespo\u010d\u00edv\u00e1 jednodu\u0161e v tom, zda Retatrutid nebo Tirzepatid vyvol\u00e1v\u00e1 v\u011bt\u0161\u00ed \u010d\u00edselnou zm\u011bnu t\u011blesn\u00e9 hmotnosti, ale zda p\u0159id\u00e1n\u00ed vyv\u00e1\u017een\u00e9 aktivity receptoru pro glukagon smyslupln\u011b m\u011bn\u00ed metabolick\u00e9 \u00fa\u010dinky dosa\u017eiteln\u00e9 kombinovan\u00fdm agonismem GIP a GLP-1.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">\u010casto kladen\u00e9 ot\u00e1zky<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Je Retatrutide tot\u00e9\u017e co Tirzepatide?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ne. Oba aktivuj\u00ed receptory GIP a GLP-1, ale Retatrutid nav\u00edc aktivuje glukagonov\u00fd receptor. Tirzepatid je proto klasifikov\u00e1n jako du\u00e1ln\u00ed agonista, zat\u00edmco Retatrutid je trojit\u00fd agonista.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Hlavn\u00ed rozd\u00edl mezi Retatrutidem a Tirzepatidem spo\u010d\u00edv\u00e1 v po\u010dtu hormon\u00e1ln\u00edch receptor\u016f, na kter\u00e9 p\u016fsob\u00ed. Tirzepatide je du\u00e1ln\u00ed agonistou receptor\u016f pro GLP-1 a GIP, zat\u00edmco Retatrutide je trojit\u00fdm agonistou, co\u017e znamen\u00e1, \u017ee stimuluje receptory pro GLP-1, GIP a nav\u00edc i pro glukagon (GCG). D\u00edky tomuto t\u0159et\u00edmu mechanismu ukazuje Retatrutide v dosavadn\u00edch studi\u00edch je\u0161t\u011b vy\u0161\u0161\u00ed potenci\u00e1l pro \u00fabytek hmotnosti.<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Hlavn\u00edm farmakologick\u00fdm rozd\u00edlem je aktivita glukagonov\u00e9ho receptoru. Tirzepatid c\u00edl\u00ed na receptory GIP a GLP-1, zat\u00edmco Retatrutid c\u00edl\u00ed na receptory GIP, GLP-1 a glukagonu.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Je Retatrutide siln\u011bj\u0161\u00ed ne\u017e Tirzepatide?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Publikovan\u00e9 studie zaznamenaly podstatn\u00e9 sn\u00ed\u017een\u00ed hmotnosti u obou l\u00e1tek, av\u0161ak v\u00fdsledky z odd\u011blen\u00fdch klinick\u00fdch studi\u00ed by nem\u011bly b\u00fdt interpretov\u00e1ny jako p\u0159\u00edm\u00e9 m\u011b\u0159\u00edtko relativn\u00ed \u00fa\u010dinnosti. Kontrolovan\u00e1 srovn\u00e1vac\u00ed studie (\u201ehead-to-head\u201c) by poskytla siln\u011bj\u0161\u00ed d\u016fkaz pro takov\u00e9 srovn\u00e1n\u00ed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Co bylo zkoum\u00e1no podrobn\u011bji?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Tirzepatid. Dokon\u010dil rozs\u00e1hl\u00fd program v\u00fdvoje ve f\u00e1zi 3 a m\u00e1 regulatorn\u00ed schv\u00e1len\u00ed pro metabolick\u00e9 indikace. Retatrutid je nov\u011bj\u0161\u00ed a nad\u00e1le prob\u00edh\u00e1 jeho klinick\u00e9 zkoum\u00e1n\u00ed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Je Retatrutid schv\u00e1len\u00fd?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ne. Retatrutid z\u016fst\u00e1v\u00e1 investigativn\u00ed slou\u010deninou a nez\u00edskal schv\u00e1len\u00ed regula\u010dn\u00edch \u00fa\u0159ad\u016f.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Je Retatrutide to sam\u00e9 jako Mounjaro nebo Zepbound?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ne. Mounjaro a Zepbound jsou komer\u010dn\u00ed l\u00e9k, jejich\u017e \u00fa\u010dinnou l\u00e1tkou je tirzepatid. Retatrutid je jin\u00fd trojit\u00fd agonista receptor\u016f GIP, GLP-1 a glukagonu, kter\u00fd je st\u00e1le ve f\u00e1zi v\u00fdzkumu a nem\u00e1 v sou\u010dasn\u00e9 dob\u011b schv\u00e1len\u00fd komer\u010dn\u00ed n\u00e1zev.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Je tirzepatid schv\u00e1len v Evrop\u011b?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ano. Tirzepatid je \u00fa\u010dinn\u00e1 l\u00e1tka v p\u0159\u00edpravku Mounjaro, kter\u00fd m\u00e1 registraci pro uv\u00e1d\u011bn\u00ed na trh v EU pro stanoven\u00e9 metabolick\u00e9 indikace.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Pro\u010d se retatrutid naz\u00fdv\u00e1 trojit\u00fd agonista?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Proto\u017ee jedna molekula aktivuje t\u0159i receptory metabolick\u00fdch hormon\u016f: GIP, GLP-1 a glukagon.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Studuj\u00ed se Retatrutid a Tirzepatid jednou t\u00fddn\u011b?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ano. Jejich prodlou\u017een\u00e9 farmakokinetick\u00e9 profily podpo\u0159ily pod\u00e1v\u00e1n\u00ed jednou t\u00fddn\u011b v klinick\u00e9m v\u00fdzkumu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Souvisej\u00edc\u00ed v\u00fdzkum<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Podrobn\u011bj\u0161\u00ed vysv\u011btlen\u00ed rozd\u00edl\u016f v signalizaci GLP-1, GIP a glukagonu najdete v na\u0161em pr\u016fvodci <strong><a href=\"https:\/\/life-peptide.com\/cs\/glp-1-metabolic-research-guide\/\" data-type=\"link\" data-id=\"https:\/\/life-peptide.com\/glp-1-metabolic-research-guide\/\">agonist\u00e9 GLP-1, du\u00e1ln\u00ed a triplicitn\u00ed receptorov\u00ed agonist\u00e9<\/a><\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">V\u00fdzkumn\u00edci mohou rovn\u011b\u017e prozkoumat profily jednotliv\u00fdch l\u00e1tek pro <a href=\"https:\/\/life-peptide.com\/cs\/product\/retatrutide-10-mg\/\" data-type=\"product\" data-id=\"331\"><strong>Retatrutid<\/strong> <\/a>a <strong><a href=\"https:\/\/life-peptide.com\/cs\/product\/tirzepatide-10-mg\/\" data-type=\"product\" data-id=\"309\">Tirzepatid<\/a><\/strong>, v\u010detn\u011b analytick\u00fdch specifikac\u00ed, d\u00e1vkov\u00e9 dokumentace a souvisej\u00edc\u00edch v\u00fdzkumn\u00fdch informac\u00ed.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Reference<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Jastreboff AM a kol. <em>Trojit\u00fd hormon\u00e1ln\u00ed receptorov\u00fd agonista retatrutid p\u0159i obezit\u011b \u2013 klinick\u00e1 studie f\u00e1ze 2. New England Journal of Medicine<\/em>. 2023.<\/li>\n\n\n\n<li>Jastreboff AM a kol. <em>Tirzepatid jednou t\u00fddn\u011b k l\u00e9\u010db\u011b obezity. New England Journal of Medicine<\/em>. 2022.<\/li>\n\n\n\n<li>Rosenstock J, et al. <em>Retatrutid, agonista receptor\u016f pro GIP, GLP-1 a glukagon, u lid\u00ed s diabetem 2. typu: randomizovan\u00e1, dvojit\u011b zaslepen\u00e1, placebem a aktivn\u00ed l\u00e1tkou kontrolovan\u00e1 paraleln\u00ed studie f\u00e1ze 2. The Lancet<\/em>. 2023.<\/li>\n\n\n\n<li>Evropsk\u00e1 agentura pro l\u00e9\u010div\u00e9 p\u0159\u00edpravky. <em>Mounjaro (tirzepatide): Evropsk\u00e1 ve\u0159ejn\u00e1 hodnot\u00edc\u00ed zpr\u00e1va<\/em>.<\/li>\n\n\n\n<li>Eli Lilly and Company. <em>Klinick\u00fd v\u00fdvoj retatrutidu a novinky ohledn\u011b programu TRIUMPH.<\/em><\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"<p>Retatrutide vs Tirzepatide: what\u2019s the difference? Retatrutide and Tirzepatide are two closely related metabolic peptides, but they differ in one fundamental respect: Tirzepatide activates two metabolic hormone receptors, while Retatrutide activates three. Tirzepatide is a dual GIP\/GLP-1 receptor agonist with an extensive clinical evidence base and regulatory approval for metabolic indications. Retatrutide adds glucagon receptor [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-1342","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/pages\/1342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/comments?post=1342"}],"version-history":[{"count":2,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/pages\/1342\/revisions"}],"predecessor-version":[{"id":1344,"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/pages\/1342\/revisions\/1344"}],"wp:attachment":[{"href":"https:\/\/life-peptide.com\/cs\/wp-json\/wp\/v2\/media?parent=1342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}